CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
E2805 | ECOG | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
N1048 | NCCTG | N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision | Adult CIRB - Late Phase Emphasis | Completed |
ACOSOG-Z1031 | ACSOG | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
A031102 | Alliance | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel; Ifosfamide; and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
S1613 | SWOG | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification | Adult CIRB - Late Phase Emphasis | Available to Open |
S1608 | SWOG | Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-GY016 | NRG | A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary | Adult CIRB - Late Phase Emphasis | Available to Open |
E2108 | ECOG | A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed |
EA5123 | ECOG-ACRIN | Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC | Adult CIRB - Late Phase Emphasis | Completed |
NRG-GY008 | NRG | A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations | Adult CIRB - Late Phase Emphasis | Completed |